Each of these rates a “D” (“sell”) or “F” overall (“strong sell”). Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures.
Investor Place · 1 day ago
Trius Therapeutics (TSRX) is a recent stock that our investment group has been buying. Our last buy was Sarepta Therapeutics (NASDAQ:SRPT) which is up 10% in the last 2 weeks. Biggest winners include Map Pharmaceuticals (which was eventually …
Seeking Alpha · 7/8/2013
TSRX). Last quarter the company had an EPS of -0.38 compared to -0.22 from the year before. In the past 3 months, the stock is up 43%, but it doesn’t have a PE and key insiders have been selling the stock. Some of the insiders selling the stock included ...
Forbes · ByKai Petainen · 6/5/2013
More from Bing News
Trius Therapeutics, Inc. (NASDAQ: TSRX) filed a registration statement with the SEC for an initial public offering of its common stock. The proposed maximum aggregate offering price is $86.25 million. The company plans to list on the NASDAQ under the …
StreetInsider · 11/6/2009
SAN DIEGO, Aug 05, 2013 (GLOBE NEWSWIRE via COMTEX) -- The Shareholders Foundation, Inc. announces that an investor who currently holds Trius Therapeutics, Inc. (TSRX) shares filed ... and other legal related news to the stock/financial market.
Market Watch · 8/5/2013
If anything, that's the time to get out. The time to get in was before TSRX confirmed one of its drugs' trials came out of that phase of testing looking very promising. The official news was so good, the stock's only down 10% after opening 6% higher.
Smallcap Network · ByJames E. Brumley · 12/19/2011
Today, I list small cap companies I believe are top acquisition targets for large pharma ... Buy-outs are hard to predict in general, and in many ways, holding stock in a company that receives a tender offer is similar to holding a winning lottery ticket.
Trefis · 5/31/2013
Trius ( TSRX) completed an equity offering on Friday, January 19 in which it sold ... bacteremia and other indications thus reducing the $12 million quarterly burn rate. The stock closed at $5.23 on Thursday, January 28th, and after the announcement ...
NASDAQ · 1/21/2013
On May 13, 2012, Trius Therapeutics (TSRX) reported financial results for the first quarter ... Results in the first quarter included a $2.4 million non-cash gain for revaluation of the common stock warrant liability. As Trius stock move down, the fair ...
Yahoo Finance · 5/9/2012
Trius Therapeutics, Inc. Also on July 30, 2013, Cubist Pharmaceuticals announced that it would purchase Trius Therapeutics (NASDAQ: TSRX) common stock for $13.50 per share, with an additional Contingency Value Right of $2 per share. The firm’s ...
Bloomberg · 8/1/2013